Hair follicle-derived IL-7 and IL-15 are crucial for maintaining skin-resident memory T cells and could be targeted for treating skin diseases and lymphoma.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.
Finasteride can reduce neuroactive steroids, causing side effects like depression, anxiety, and sexual dysfunction. Some users experience persistent symptoms after stopping finasteride, while others use alternative treatments like topical solutions.